• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Adverum Biotechnologies Inc.

    2/15/24 4:17:58 PM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ADVM alert in real time by email
    SC 13G 1 d656327dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

     

    Adverum Biotechnologies, Inc.

    (Name of Issuer)

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

    00773U108

    (CUSIP Number)

    February 8, 2024

    (Date of Event Which Requires Filing of This Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 00773U108   13G

     

     1.   

     NAMES OF REPORTING PERSONS

     

     TCG Crossover GP II, LLC

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.    

     SOLE VOTING POWER

     

     0

       6.   

     SHARED VOTING POWER

     

     20,763,572 (1)(2)

       7.   

     SOLE DISPOSITIVE POWER

     

     0

       8.   

     SHARED DISPOSITIVE POWER

     

     20,763,572 (1)(2)

     9.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     20,763,572 (1)(2)

    10.  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

     ☐

    11.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     9.9% (2)(3)

    12.  

     TYPE OF REPORTING PERSON (see instructions)

     

     OO

     

    (1)

    These securities are held of record by TCG Crossover II (as defined in Item 2(a) below). TCG Crossover GP II (as defined in Item 2(a) below) is the general partner of TCG Crossover II and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP II and may be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Consists of (i) 20,083,395 shares of Common Stock (as defined in Item 2(d) below) of the Issuer (as defined in Item 1(a) below) and (ii) 680,177 shares of Common Stock, issuable upon exercise of certain Pre-Funded Warrants (as defined and described in the Form 8-K (as defined in footnote (3) below)). This total excludes 69,823 shares of Common Stock issuable upon exercise of certain Pre-Funded Warrants because the Pre-Funded Warrants may not be exercised to the extent that doing so would result in the holder of the Pre-Funded Warrants (together with the holder’s affiliates and any other persons acting as a group together with the holder or any of the holder’s affiliates) beneficially owning more than 9.99% of the shares of Common Stock then outstanding immediately after giving effect to such exercise (the “Beneficial Ownership Limitation”).

    (3)

    Based on 207,163,393 shares of Common Stock expected to be outstanding on February 8, 2024, following the closing of its private placement offerings, as disclosed by the Issuer in its Current Report on Form 8-K filed with the Securities and Exchange Commission (the “Commission”) on February 5, 2024 (the “Form 8-K”), plus 680,177 shares of Common Stock issuable upon exercise of certain Pre-Funded Warrants held of record by TCG Crossover II.


    CUSIP No. 00773U108   13G

     

     1.   

     NAMES OF REPORTING PERSONS

     

     TCG Crossover Fund II, L.P.

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.    

     SOLE VOTING POWER

     

     0

       6.   

     SHARED VOTING POWER

     

     20,763,572 (1)(2)

       7.   

     SOLE DISPOSITIVE POWER

     

     0

       8.   

     SHARED DISPOSITIVE POWER

     

     20,763,572 (1)(2)

     9.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     20,763,572 (1)(2)

    10.  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

     ☐

    11.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     9.9% (2)(3)

    12.  

     TYPE OF REPORTING PERSON (see instructions)

     

     PN

     

    (1)

    These securities are held of record by TCG Crossover II. TCG Crossover GP II is the general partner of TCG Crossover II and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP II and may be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Consists of (i) 20,083,395 shares of Common Stock held of record by TCG Crossover II and (ii) 680,177 shares of Common Stock, issuable upon exercise of certain Pre-Funded Warrants held of record by TCG Crossover II. This total excludes 69,823 shares of Common Stock issuable upon exercise of certain Pre-Funded Warrants as a result of the Beneficial Ownership Limitation.

    (3)

    Based on 207,163,393 shares of Common Stock outstanding, as disclosed by the Issuer in its Form 8-K, plus 680,177 shares of Common Stock issuable upon exercise of certain Pre-Funded Warrants held of record by TCG Crossover II.


    CUSIP No. 00773U108   13G

     

     1.   

     NAMES OF REPORTING PERSONS

     

     Chen Yu

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States of America

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.    

     SOLE VOTING POWER

     

     0

       6.   

     SHARED VOTING POWER

     

     20,763,572 (1)(2)

       7.   

     SOLE DISPOSITIVE POWER

     

     0

       8.   

     SHARED DISPOSITIVE POWER

     

     20,763,572 (1)(2)

     9.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     20,763,572 (1)(2)

    10.  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

     ☐

    11.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     9.9% (2)(3)

    12.  

     TYPE OF REPORTING PERSON (see instructions)

     

     IN

     

    (1)

    These securities are held of record by TCG Crossover II. TCG Crossover GP II is the general partner of TCG Crossover II and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP II and may be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Consists of (i) 20,083,395 shares of Common Stock held of record by TCG Crossover II and (ii) 680,177 shares of Common Stock, issuable upon exercise of certain Pre-Funded Warrants held of record by TCG Crossover II. This total excludes 69,823 shares of Common Stock issuable upon exercise of certain Pre-Funded Warrants as a result of the Beneficial Ownership Limitation.

    (3)

    Based on 207,163,393 shares of Common Stock outstanding, as disclosed by the Issuer in its Form 8-K, plus 680,177 shares of Common Stock issuable upon exercise of certain Pre-Funded Warrants held of record by TCG Crossover II.


    CUSIP No. 00773U108   13G

     

    Item 1(a).

    Name of Issuer:

    Adverum Biotechnologies, Inc. (the “Issuer”).

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    100 Cardinal Way

    Redwood City, CA 94063

     

    Item 2(a).

    Name of Person Filing:

    This joint statement on Schedule 13G is being filed by TCG Crossover Fund II, L.P. (“TCG Crossover II”), TCG Crossover GP II, LLC (“TCG Crossover GP II” and together with TCG Crossover II, the “Reporting Entities”) and Chen Yu (the “Reporting Individual”). The Reporting Entities and the Reporting Individual are collectively referred to as the “Reporting Persons.” The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G. The agreement among the Reporting Persons to file jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act is attached to this Statement as Exhibit 1. Other than those securities reported herein as being held directly by such Reporting Person, each Reporting Person disclaims beneficial ownership of all securities reported in this Statement except to the extent of such Reporting Person’s pecuniary interest therein.

     

    Item 2(b)

    Address of Principal Business Office, or if None, Residence:

    The address of the principal business office of each Reporting Person is 705 High St., Palo Alto, CA 94301.

     

    Item 2(c).

    Citizenship:

    TCG Crossover GP II is a limited liability company organized under the laws of the State of Delaware. TCG Crossover II is a limited partnership organized under the laws of the State of Delaware. The Reporting Individual is a citizen of the United States of America.

     

    Item 2(d).

    Title of Class of Securities:

    Common Stock, $0.0001 par value per share (“Common Stock”).

     

    Item 2(e).

    CUSIP Number:

    00773U108

     

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

    Not applicable.


    CUSIP No. 00773U108   13G

     

    Item 4.

    Ownership.

     

      (a)

    Amount beneficially owned:

    See Row 9 of the cover page for each Reporting Person and the corresponding footnotes.*

     

      (b)

    Percent of class:

    See Row 11 of the cover page for each Reporting Person and the corresponding footnotes.*

     

      (c)

    Number of shares as to which the person has:

     

      (i)

    Sole power to vote or to direct the vote

    See Row 5 of the cover page for each Reporting Person and the corresponding footnotes.*

     

      (ii)

    Shared power to vote or to direct the vote

    See Row 6 of the cover page for each Reporting Person and the corresponding footnotes.*

     

      (iii)

    Sole power to dispose or to direct the disposition of

    See Row 7 of the cover page for each Reporting Person and the corresponding footnotes.*

     

      (iv)

    Shared power to dispose or to direct the disposition of

    See Row 8 of the cover page for each Reporting Person and the corresponding footnotes.*

     

    *

    Except to the extent of his or its pecuniary interest therein, each Reporting Person disclaims beneficial ownership of such shares of Common Stock, except for the shares, if any, such Reporting Person holds of record.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    Not applicable.

     

    Item 6.

    Ownership of More Than Five Percent on Behalf of Another Person.

    Under certain circumstances set forth in the limited partnership agreement of TCG Crossover II and the limited liability company agreement of TCG Crossover GP II, the general and limited partners or members, as the case may be, of each of such entities may be deemed to have the right to receive dividends from, or the proceeds from, the sale of securities of the Issuer owned by each such entity of which they are a partner or member, as the case may be.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not applicable.


    CUSIP No. 00773U108   13G

     

    Item 9.

    Notice of Dissolution of the Group.

    Not applicable.

     

    Item 10.

    Certifications.

    Not Applicable

    Material to be Filed as Exhibits.

    Exhibit 1 – Joint Filing Agreement.


    CUSIP No. 00773U108   13G

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 15, 2024

     

    TCG Crossover Fund II, L.P.
    By:   TCG Crossover GP II, LLC
    Its:   General Partner
    By:   /s/ Craig Skaling
      Authorized Signatory
    TCG Crossover GP II, LLC
    By:   /s/ Craig Skaling
      Authorized Signatory
    /s/ Craig Skaling, as attorney-in-fact for Chen Yu
    Chen Yu
    Get the next $ADVM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADVM

    DatePrice TargetRatingAnalyst
    11/17/2025Buy → Neutral
    H.C. Wainwright
    6/25/2024$25.00Outperform
    Oppenheimer
    4/30/2024$30.00Buy
    H.C. Wainwright
    7/7/2022$4.00Hold → Buy
    Truist
    7/23/2021Hold → Neutral
    Cantor Fitzgerald
    7/23/2021$23.00 → $3.00Overweight → Neutral
    Cantor Fitzgerald
    7/23/2021$5.00 → $2.00Market Perform
    SVB Leerink
    More analyst ratings

    $ADVM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Adverum Biotech downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Adverum Biotech from Buy to Neutral

    11/17/25 9:39:07 AM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Oppenheimer initiated coverage on Adverum Biotech with a new price target

    Oppenheimer initiated coverage of Adverum Biotech with a rating of Outperform and set a new price target of $25.00

    6/25/24 8:10:21 AM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright initiated coverage on Adverum Biotech with a new price target

    H.C. Wainwright initiated coverage of Adverum Biotech with a rating of Buy and set a new price target of $30.00

    4/30/24 6:15:49 AM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADVM
    SEC Filings

    View All

    SEC Form 15-12G filed by Adverum Biotechnologies Inc.

    15-12G - Adverum Biotechnologies, Inc. (0001501756) (Filer)

    12/19/25 4:00:16 PM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed by Adverum Biotechnologies Inc.

    EFFECT - Adverum Biotechnologies, Inc. (0001501756) (Filer)

    12/12/25 12:15:05 AM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed by Adverum Biotechnologies Inc.

    EFFECT - Adverum Biotechnologies, Inc. (0001501756) (Filer)

    12/12/25 12:15:03 AM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADVM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO, PRESIDENT AND DIRECTOR Fischer Laurent exercised 150,000 shares at a strike of $4.20 and was granted 500,000 units of Common Stock - Performance Stock Units, closing all direct ownership in the company (SEC Form 4)

    4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)

    12/10/25 1:52:31 PM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CHIEF OPERATING OFFICER Soparkar Peter was granted 150,000 units of Common Stock - Performance Stock Units, closing all direct ownership in the company (SEC Form 4)

    4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)

    12/10/25 1:49:41 PM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Medical Officer Ozden Rabia Gurses was granted 85,000 units of Common Stock - Performance Stock Units, closing all direct ownership in the company (SEC Form 4)

    4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)

    12/10/25 1:46:33 PM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADVM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $ADVM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition

    INDIANAPOLIS, Dec. 9, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY)  and Adverum Biotechnologies, Inc. (NASDAQ:ADVM) today announced that the tender offer (the "Offer") by Flying Tigers Acquisition Corporation ("Purchaser"), a direct wholly-owned subsidiary of Lilly, to purchase all of the issued and outstanding shares ("Shares") of Adverum's common stock in exchange for (i) $3.56 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding, plus (ii) one non-tradable contingent value right ("CVR") per Share, which represents the contractual right to receive up to two contingent cash payments of up to an aggregate of $8.91 per CVR, net to the st

    12/9/25 8:28:00 AM ET
    $ADVM
    $LLY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Adverum Reminds Stockholders to Tender their Shares into the Offer by Lilly

    REDWOOD CITY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of intravitreal gene therapy as a potential One And DoneTM treatment to preserve sight for life, today announced that it has mailed a letter to its stockholders in connection with its pending transaction to be acquired by Eli Lilly and Company ("Lilly"). In accordance with the merger agreement between Lilly and Adverum, on November 7, 2025 Lilly commenced a tender offer to acquire all of the outstanding shares of Adverum's common stock for a per share price of (1) $3.56 per share in cash payable at closing plus (2) one non-transferable contingent

    12/1/25 7:00:00 AM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lilly to Acquire Adverum Biotechnologies

    Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose  Acquisition aligns Lilly's genetic medicine capabilities with opportunity to expand gene therapy's potential to alleviate the burden of age-related diseases  INDIANAPOLIS and REDWOOD CITY, Calif., Oct. 24, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of intravitreal gene therapy with the aim of preserving sight for life in highly prevalent ocular diseases, today announced a definitive agreement for Lilly to acquire Adve

    10/24/25 8:30:00 AM ET
    $ADVM
    $LLY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    CEO, PRESIDENT AND DIRECTOR Fischer Laurent bought $553,917 worth of shares (128,699 units at $4.30), increasing direct ownership by 177% to 201,513 units (SEC Form 4)

    4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)

    12/8/25 9:45:06 PM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CHIEF OPERATING OFFICER Soparkar Peter bought $211,000 worth of shares (50,000 units at $4.22), increasing direct ownership by 166% to 80,189 units (SEC Form 4)

    4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)

    12/8/25 9:45:04 PM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: Large owner Leonard Braden Michael bought $188,931 worth of shares (37,000 units at $5.11), increasing direct ownership by 35% to 141,800 units (SEC Form 4)

    4/A - Adverum Biotechnologies, Inc. (0001501756) (Issuer)

    4/28/25 3:31:52 PM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADVM
    Leadership Updates

    Live Leadership Updates

    View All

    Lilly to Acquire Adverum Biotechnologies

    Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose  Acquisition aligns Lilly's genetic medicine capabilities with opportunity to expand gene therapy's potential to alleviate the burden of age-related diseases  INDIANAPOLIS and REDWOOD CITY, Calif., Oct. 24, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of intravitreal gene therapy with the aim of preserving sight for life in highly prevalent ocular diseases, today announced a definitive agreement for Lilly to acquire Adve

    10/24/25 8:30:00 AM ET
    $ADVM
    $LLY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones

    - 52-week LUNA and 4-year OPTIC data, alongside Phase 3 trial design updates, anticipated in Q4 2024 - Appointed Jason Mitchell as chief commercial officer - On track to initiate pivotal program in 1H 2025 - $153.2 million in cash, cash equivalents and short-term investments expected to fund operations into late 2025 REDWOOD CITY, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today reported financial results for the third quarter of 2024 and provided updates to anticipated milestones. "We remain laser focused on initiating

    11/4/24 4:39:45 PM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program

    REDWOOD CITY, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the appointment of Jason L. Mitchell as chief commercial officer. Mr Mitchell brings to Adverum over 20 years of commercial experience, including in retinal disease, and most recently oversaw the successful launch of SYFOVRE® in geographic atrophy (GA). In his new role, Mr. Mitchell will be responsible for setting the launch strategy and building the commercial infrastructure for ixoberogene soroparvovec (Ixo-vec), Adverum's potential one-time intravitreal (IVT) injec

    10/16/24 8:00:00 AM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADVM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Adverum Biotechnologies Inc.

    SC 13G/A - Adverum Biotechnologies, Inc. (0001501756) (Subject)

    11/14/24 6:57:12 PM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Adverum Biotechnologies Inc.

    SC 13G/A - Adverum Biotechnologies, Inc. (0001501756) (Subject)

    11/14/24 6:40:56 PM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Adverum Biotechnologies Inc.

    SC 13G/A - Adverum Biotechnologies, Inc. (0001501756) (Subject)

    11/14/24 4:05:12 PM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADVM
    Financials

    Live finance-specific insights

    View All

    Adverum Biotechnologies to Host Webcast to Review Clinical Data from the 26-Week Interim Analysis of the Ongoing LUNA Phase 2 Trial in Wet AMD Being Presented at ASRS Annual Meeting

    REDWOOD CITY, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will host a webcast to review the interim 26-week landmark data from its ongoing LUNA Phase 2 study of ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related macular degeneration (wet AMD) being presented at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting. The webcast will be held on Wednesday, July 17 at 8:00 a.m. ET and will include a presentation from Dr. Charles C. Wykoff, Director of Res

    7/10/24 8:00:00 AM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024

    - Preliminary safety and efficacy data from ongoing LUNA Phase 2 study of Ixo-vec for the treatment of wet AMD will be presented at the 47th Annual Meeting of the Macula Society, with company-sponsored webcast on Thursday, February 8, 2024 at 8:00am ET - REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will host a webcast to review preliminary efficacy and safety data from its ongoing LUNA Phase 2 study of ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related

    2/1/24 5:30:00 PM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society

    REDWOOD CITY, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the initial LUNA preliminary efficacy and safety data will be presented at the upcoming 47th Annual Meeting of the Macula Society, being held February 7 – 10, 2024. "We are very pleased to have the opportunity to present our initial Phase 2 efficacy and safety data from the LUNA study at the Macula Society meeting" stated Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies. "We recently received confirmation that ou

    12/7/23 4:05:00 PM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care